Preserving renal function is important in patients with atrial fibrillation and diabetes

Atrial fibrillation in patients with diabetes and renal impairment.



For full prescribing information, refer to the package insert approved by the Medicines Authority (SAHPRA).

XARELTO® 10 (Rivaroxaban 10 mg): South Africa:  S4  Reg. No.: 42/8.2/1046; Namibia:  NS2  10/8.2/0463; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5362; Mauritius: R12697/02/14.

XARELTO® 15 (Rivaroxaban 15 mg): South Africa:  S4  Reg. No.: 46/8.2/0111; Namibia:  NS2  12/8.2/0006; Botswana:  S2  BOT1302278; Zimbabwe: PP10 Reg. 2017/10.2/5363; Mauritius: R11772/02/14.

XARELTO® 20 (Rivaroxaban 20 mg): South Africa:  S4  Reg. No.: 46/8.2/0112; Namibia:  NS2  12/8.2/0007; Botswana:  S2  BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364; Mauritius: R12698/02/14. 

Applicant/HCR: Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609.